Natural Resources Defense Council, Inc. v. United States Food & Drug Administration
760 F.3d 151
2d Cir.2014Background
- FDA regulates new animal drugs under 21 U.S.C. § 360b(a); withdrawal of approvals follows findings that drugs are not shown to be safe.
- In 1977, FDA issued NOOHs for penicillin and tetracycline in animal feed, signaling safety concerns and a proposed withdrawal process.
- FDA never completed the 1977 withdrawal hearings; in 1983 the petitions were denied, with stays pending further studies.
- Public-interest groups sued in SDNY seeking mandatory hearings and withdrawal; FDA pursued voluntary compliance measures instead.
- District court granted summary judgment for NRDC on the NOOH withdrawal issue and on petition denial; appellate court reversed on these points.
- Judge Katzmann dissented, urging that § 360b(e)(l)(B) requires withdrawal proceedings after a preliminary finding of not showing safety, and criticizing the FDA’s voluntary approach.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Does § 360b(e)(l)(B) require withdrawal hearings after a preliminary finding of not safety? | NRDC argues two findings are implicit: pre-hearing finding triggers hearing and post-hearing finding triggers withdrawal. | FDA argues single finding after hearing triggers withdrawal; hearings may be discretionary. | Discretionary; required sequence: hearing following a preconditions-based finding before withdrawal. |
| Is FDA's denial of the 1999 and 2005 citizen petitions arbitrary or capricious? | FDA ignored substantial safety data; relied on cost/voluntary-compliance considerations outside statutory scope. | FDA properly weighed factors and pursued alternatives consistent with its regulatory strategy. | No; denial not arbitrary or capricious under Massachusetts v. EPA; agency discretion respected. |
| Does Chevron deference apply to FDA interpretations of § 360b(e)(l)? | Regulations support pre-hearing findings; agency interpretations should be given deference. | Regulations do not unambiguously resolve the interpretation; Chevron deference not controlling. | Chevron deference not controlling; statute ambiguous and regulatory texts do not settle the question. |
| Are withdrawal proceedings more like enforcement or rulemaking, affecting reviewability? | Withdrawal proceedings are enforcement-like; agency must act on safety findings. | Withdrawals resemble rulemaking; discretion to pursue or delay is acceptable. | Withdrawal proceedings are discretionary but subject to statutory limits; Massachusetts guidance applies. |
| What is the appropriate path for addressing safety concerns beyond penicillin/tetracycline? | FDA should withdraw approvals for other medically important antibiotics with subtherapeutic use. | FDA may pursue voluntary measures and phased reductions instead of broad withdrawals. | Agency may pursue voluntary measures; not compelled to withdraw absent a final safety finding and hearing. |
Key Cases Cited
- Massachusetts v. EPA, 549 U.S. 497 (U.S. (2007)) (mandatory action limited by statutory text; endangerment findings must follow proper scope)
- Brown & Williamson Tobacco Corp. v. FDA, 529 U.S. 120 (U.S. (2000)) (agency findings and regulatory authority boundaries under FDA Act)
- Heckler v. Chaney, 470 U.S. 821 (U.S. (1985)) (presumption against judicial review of agency enforcement decisions)
- New York Public Interest Research Group v. Whitman, 321 F.3d 316 (2d Cir. 2003) (analysis of agency discretion vs. statutory mandate in enforcement context)
- U.S. Gypsum Co. v. United States, 438 U.S. 422 (U.S. (1978)) (background principles for interpreting agency findings and procedures)
- United States v. Pacheco, 225 F.3d 148 (2d Cir. 2000) (statutory interpretation in administrative law context)